Vaccination

Production of Russia’s Sputnik vaccine to begin in Serbia: makers

Credit: Unsplash/CC0 Public Domain

Moscow on Wednesday announced the start of production of its Sputnik V coronavirus vaccine in Serbia, the first European country outside Russia and Belarus to begin manufacturing the jab.

“Serbia has become the first country in Southern Europe to produce Sputnik V,” the Russian Direct Investment Fund (RDIF), which has backed the financing of the vaccine, said in a statement.

A RDIF spokesman told AFP that Serbia would be the first European country apart from Russia and Belarus to produce Sputnik.

Serbia said that manufacturing would begin on May 20.

Serbian President Aleksandar Vucic is expected to visit Belgrade’s Torlak Institute, where the vaccine will be manufactured, on Thursday.

“The first series of control vials of the Sputnik V vaccine were filled at the Torlak Institute” on Wednesday, Nenad Popovic, Serbia’s innovation minister, said on Twitter.

Serbia began vaccinations with Sputnik in early January.

“The scale of vaccination may be significantly increased thanks to the launch of local production,” RDIF chief executive Kirill Dmitriev said in a statement.

The vaccine could be exported to other countries in the region at a later stage, the fund said.

Russia registered Sputnik V last August ahead of large-scale clinical trials, prompting concern among experts over the fast-track process.

But later reviews have been largely positive, with the medical journal The Lancet publishing results showing it to be safe and more than 90 percent effective.

The vaccine has now been registered for use in dozens of countries.


Follow the latest news on the coronavirus (COVID-19) outbreak


© 2021 AFP

Citation:
Production of Russia’s Sputnik vaccine to begin in Serbia: makers (2021, April 14)
retrieved 14 April 2021
from https://medicalxpress.com/news/2021-04-production-russia-sputnik-vaccine-serbia.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Ad Block Detected

Welcome to Mediexpose, Please support our journalism by allowing ads. With support from readers like you, we can continue to deliver the best. You can support us free by simply allowing ads.